Hangzhou Tigermed Consulting Co., Ltd. Class H (HK:3347)
:3347
Want to see HK:3347 full AI Analyst Report?
Top Page
Hangzhou Tigermed Consulting Co., Ltd. Class H
(3347)
Select Model
Select Model
Rating:62Neutral
Price Target:
HK$33.00
â–Ľ(-38.89% Downside)
Action:Reiterated
Date:04/30/26
The score is supported primarily by solid financial performance (low leverage, stabilized margins, and positive free cash flow). It is held back by weak technicals (below key moving averages with negative MACD) and a relatively expensive valuation (high P/E with a modest dividend yield).
Positive Factors
Comprehensive CRO service offering
Tigermed’s end-to-end CRO capabilities across planning, operations, data, regulatory and safety create durable revenue streams tied to multi-phase trials. A broad service set and international delivery network support cross-selling, longer contract durations and stickier client relationships over quarters.
Negative Factors
Margin and return compression
Profitability has meaningfully compressed from 2021–2022 highs and experienced a 2024 dip before a partial recovery. Sustained lower margins reduce internal funding for growth, constrain reinvestment into service capabilities, and indicate tougher pricing or mix shifts that could persist across multiple reporting periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Comprehensive CRO service offering
Tigermed’s end-to-end CRO capabilities across planning, operations, data, regulatory and safety create durable revenue streams tied to multi-phase trials. A broad service set and international delivery network support cross-selling, longer contract durations and stickier client relationships over quarters.
Read all positive factors
Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$35.30B
Dividend Yield0.8%
Average Volume (3M)2.64M
Price to Earnings (P/E)42.5
Beta (1Y)1.86
Revenue Growth10.65%
EPS Growth134.38%
CountryHK
Employees10,185
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.90
Shares Outstanding123,124,800
10 Day Avg. Volume1,735,173
30 Day Avg. Volume2,642,557
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$54.07Price Target Upside0.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.29
Revenue Forecast (FY)HK$8.75B
Hangzhou Tigermed Consulting Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Hangzhou Tigermed Consulting Co., Ltd. operates as a contract research organization (CRO) across the People's Republic of China and globally, offering an extensive suite of services. The company's operations are divided into two primary segments: ...
How the Company Makes Money
Tigermed primarily makes money by charging customers (pharma/biotech and medical device sponsors) service fees under CRO contracts to run and support clinical development programs. Key revenue streams typically include: (1) Clinical trial services...
Hangzhou Tigermed Consulting Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
86
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.07B | 6.83B | 6.60B | 7.38B | 7.09B | 5.21B |
| Gross Profit | 1.88B | 1.87B | 2.24B | 2.85B | 2.81B | 2.27B |
| EBITDA | 1.83B | 1.42B | 1.13B | 2.91B | 2.93B | 3.90B |
| Net Income | 903.80M | 887.89M | 405.14M | 2.02B | 2.01B | 2.87B |
Balance Sheet | ||||||
| Total Assets | 28.80B | 28.36B | 28.67B | 29.68B | 27.45B | 23.74B |
| Cash, Cash Equivalents and Short-Term Investments | 2.20B | 1.84B | 2.13B | 7.46B | 7.88B | 8.57B |
| Total Debt | 1.53B | 1.47B | 2.63B | 2.83B | 2.80B | 1.19B |
| Total Liabilities | 4.24B | 4.10B | 4.61B | 5.23B | 4.77B | 3.14B |
| Stockholders Equity | 20.92B | 20.96B | 20.67B | 21.03B | 19.58B | 18.12B |
Cash Flow | ||||||
| Free Cash Flow | 1.17B | 903.72M | 740.45M | 836.68M | 908.90M | 1.06B |
| Operating Cash Flow | 1.39B | 1.12B | 1.10B | 1.15B | 1.36B | 1.42B |
| Investing Cash Flow | 1.01B | 491.56M | -4.74B | -1.53B | -2.79B | -2.78B |
| Financing Cash Flow | -1.78B | -1.93B | -1.70B | -7.81M | 809.25M | -163.09M |
Hangzhou Tigermed Consulting Co., Ltd. Class H Technical Analysis
Negative
54.00
Price Trends
36.54
Negative
41.42
Negative
42.90
Negative
Market Momentum
-1.31
Negative
40.88
Neutral
58.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3347, the sentiment is Negative. The current price of 54 is above the 20-day moving average (MA) of 31.38, above the 50-day MA of 36.54, and above the 200-day MA of 42.90, indicating a bearish trend. The MACD of -1.31 indicates Negative momentum. The RSI at 40.88 is Neutral, neither overbought nor oversold. The STOCH value of 58.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3347.
Hangzhou Tigermed Consulting Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$352.13B | 14.93 | 27.31% | 1.84% | 19.90% | 86.59% | |
74 Outperform | HK$28.10B | 53.65 | 5.98% | 0.15% | -13.51% | 33.63% | |
63 Neutral | HK$58.87B | 36.35 | 16.29% | ― | 46.83% | 36.46% | |
62 Neutral | HK$35.30B | 42.51 | 3.69% | 0.80% | 10.65% | 134.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
31.66
-5.27
-14.26%
HK:2359
WuXi AppTec Co., Ltd. Class H
132.80
59.67
81.58%
HK:6127
JOINN Laboratories (China) Co., Ltd. Class H
16.82
1.91
12.81%
HK:6667
Mega Genomics Limited
7.02
>-0.01
-0.10%
HK:9860
ADICON Holdings Limited
3.96
-2.52
-38.89%
HK:2268
WuXi XDC Cayman, Inc.
48.16
7.31
17.89%
Hangzhou Tigermed Consulting Co., Ltd. Class H Corporate Events
Tigermed shareholders approve all resolutions at June extraordinary meetings
Jun 9, 2026
Hangzhou Tigermed Consulting Co., Ltd. held its 2026 second extraordinary general meeting and separate A share and H share class meetings in Hangzhou on June 9, where all resolutions put to shareholders were approved by poll. The meetings were cha...
Tigermed Secures Shareholder Approval at 2025 AGM and 2026 Class Meetings
Jun 2, 2026
Hangzhou Tigermed Consulting Co., Ltd., a leading Chinese contract research organization serving pharmaceutical and biotech clients, operates through both A shares on the Shenzhen Stock Exchange and H shares in Hong Kong. Its business centers on c...
Tigermed Clarifies Board Roles to Strengthen Governance Structure
Jun 2, 2026
Hangzhou Tigermed Consulting has updated its board composition, detailing the allocation of directors across key governance committees, including strategy development, remuneration and evaluation, audit, and nomination. The announcement highlights...
Hangzhou Tigermed Overhauls Board Roles and Senior Management for Sixth Term
Jun 2, 2026
Hangzhou Tigermed Consulting Co., Ltd. announced the composition of its sixth board of directors and confirmed that executive director Dr. Ye Xiaoping has been elected chairman for the new board term starting June 2, 2026. Independent non-executiv...
Tigermed Elects Wu Hao as Employee Director for Sixth Board Term
Jun 2, 2026
Hangzhou Tigermed Consulting has announced the election of Wu Hao as the employee director for its sixth board term, following a vote at the company’s employee representative meeting. His appointment will take effect once the new board is ap...
Tigermed Updates Final 2025 Dividend Terms for Cross-Border Shareholders
Jun 2, 2026
Hangzhou Tigermed Consulting Co., Ltd., a China-based clinical research and pharmaceutical services group listed in Hong Kong, provides contract research and related consulting services to biopharmaceutical and healthcare companies. Its Hong Kong ...
Tigermed Calls June EGM to Seek Approval for A-Share Buyback Mandate
May 19, 2026
Hangzhou Tigermed Consulting Co., Ltd. has called a second extraordinary general meeting for June 9, 2026, in Hangzhou to seek shareholder approval for a special resolution authorizing the repurchase of its A shares via centralized price bidding. ...
Tigermed Calls 2026 H Shareholders’ Meeting to Approve A Share Buyback Mandate
May 19, 2026
Hangzhou Tigermed Consulting Co., Ltd. has convened a 2026 second H share class meeting in Hong Kong for holders of its H shares, to be held on June 9, 2026 after its extraordinary general and A share class meetings. The session will be conducted ...
Hangzhou Tigermed Unveils Up to RMB1 Billion A-Share Buyback Plan
May 13, 2026
Hangzhou Tigermed Consulting has unveiled a plan to repurchase between RMB500 million and RMB1 billion of its publicly held A shares through centralized price bidding, at a maximum price of RMB60 per share. The repurchased stock will be partly all...
Tigermed Says Probe Into Major Shareholders Will Not Hit Operations
May 13, 2026
Hangzhou Tigermed Consulting has issued a clarification following market speculation about whether its controlling shareholders, chairman Ye Xiaoping and director Cao Xiaochun, complied with disclosure rules on past shareholding changes. The compa...
Tigermed Directors Probed by CSRC Over Shareholding Disclosures
May 12, 2026
Hangzhou Tigermed Consulting has disclosed that two of its directors and controlling shareholders, chairman Ye Xiaoping and director Cao Xiaochun, are under investigation by the China Securities Regulatory Commission for suspected violations relat...
Hangzhou Tigermed Updates 2025 Final Dividend Terms and Tax Treatment
Apr 29, 2026
Hangzhou Tigermed Consulting has announced an updated final cash dividend for the year ended 31 December 2025, declaring a payout of RMB 1.26 per 10 shares, subject to shareholder approval on 2 June 2026. The dividend for Hong Kong shareholders wi...
Tigermed Sets 2025 AGM to Decide Dividends, Board Mandates and Governance Changes
Apr 29, 2026
Hangzhou Tigermed Consulting Co., Ltd. has called its 2025 annual general meeting for June 2, 2026 in Hangzhou, where shareholders will review the 2025 operating year, including the annual report, board report, final financial report and profit di...
Tigermed Sets 2026 H Share Class Meeting to Seek H-Share Buyback Mandate
Apr 29, 2026
Hangzhou Tigermed Consulting has called its 2026 First H Share Class Meeting for June 2, 2026 in Hangzhou, following its 2025 annual general meeting and the 2026 first A share class meeting. H shareholders on the register as of that date may atten...
Hangzhou Tigermed issues unaudited 2026 first-quarter report
Apr 28, 2026
Hangzhou Tigermed Consulting has released its unaudited first quarterly report for the 2026 financial year, prepared under China Accounting Standards for Business Enterprises. The document, published in both Chinese and English with the Chinese ve...
Tigermed Sets April 28 Board Meeting to Approve First-Quarter 2026 Results
Apr 16, 2026
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for April 28, 2026 to review and approve its first quarterly report for the period ended March 31, 2026. The meeting may also cover additional board resolutions, signaling routin...
Tigermed Plans Governance Revamp With New Vice Chairman and Expanded Co-President Roles
Mar 30, 2026
Hangzhou Tigermed Consulting Co., Ltd. has proposed amendments to its articles of association to add the role of vice chairman to its seven-member board and to increase the number of co-presidents from one to two, reflecting evolving operational a...
Hangzhou Tigermed Proposes 2025 Final Dividend With Key Details Pending
Mar 30, 2026
Hangzhou Tigermed Consulting has proposed a final ordinary cash dividend of RMB 1.26 per 10 shares for the financial year ended 31 December 2025, with payment scheduled for 31 July 2026. Key details including shareholder approval date, currency fo...
Tigermed Proposes New Three-Year Board Line-Up to Maintain Strategic Continuity
Mar 30, 2026
Hangzhou Tigermed Consulting Co., Ltd. has outlined the composition of its sixth board, proposing seven directors in line with Chinese company law and its articles of association, including one employee director. The company seeks shareholder appr...
Tigermed Lifts Headline Profit and Dividend Despite Margin Squeeze in 2025
Mar 30, 2026
Hangzhou Tigermed Consulting reported modest revenue growth for 2025, with sales rising 3.5% year-on-year to RMB 6.83 billion, while gross profit declined 16.4% and gross margin fell to 27.4%, highlighting pressure on operating efficiency. Despite...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.